Proposal to list haemodialysis equipment and products by B Braun New Zealand Pty Limited

Hospital devices Consultation Closed

PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule.

What we’re proposing

PHARMAC is seeking feedback on a proposal to list a range of haemodialysis equipment and products in Part III of Section H of the Pharmaceutical Schedule from 1 August 2021 through a provisional Agreement with B Braun New Zealand Pty Limited (“B Braun”).

Consultation closes 4pm Thursday 10 June 2021 and feedback can be emailed to

What would the effect be?

From 1 August 2021, B Braun’s range of haemodialysis equipment and products would be listed under the proposed national agreement (“Agreement”) that all DHBs may purchase under, subject to consultation and approval by PHARMAC’s Board or delegate.

The Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of haemodialysis equipment and products.

The Agreement would supersede any existing DHB contract with the supplier for the devices listed in the Agreement, unless otherwise referenced in the Agreement. Any device listed in a PHARMAC Agreement and purchased by a DHB would be at the price, terms and conditions stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.

Who we think will be interested

  • DHB staff
    • Renal dialysis staff
    • Procurement officers
  • Suppliers and wholesalers

About haemodialysis products

Haemodialysis is used to treat renal failure, both acute and chronic. The leading cause of renal failure is diabetes. Patients require treatments to be performed on average three times per week with each session lasting on average four hours.

Most treatment is provided in a DHB Hospital or DHB satellite centre, though some patients self-administer using equipment installed in their home. Acute dialysis may be required for patients in intensive care who have undergone significant trauma or illness. Acute treatment may result in the patient’s full recovery or may lead to long term chronic dialysis.

Chronic haemodialysis is usually required until either the patient changes to peritoneal dialysis, receives a kidney transplant or no longer gains benefit from treatment and enters palliative care.

Why we’re proposing this

In February 2018, PHARMAC issued a  Request for Proposal ("RFP") for the supply of haemodialysis equipment and products

The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

PHARMAC has been working with suppliers in order to seek provisional agreements and this is the final proposal to arise from that process.

Details about our proposal

PHARMAC has entered into a provisional Agreement with B Braun for the supply of a range of haemodialysis related equipment products and support services. This includes haemodialysis machines and associated consumables, maintenance, and service options (including all spare parts for the equipment), and Price-Per-Treatment (“PPT”) options as part of lease arrangements for capital expenditure. The PPT payment option is calculated using a specially designed tool that enables DHBs to select those components most appropriate to their service.

We are making the full product, pricing options and PPT calculator tool available to Procurement Departments at DHBs.

To provide feedback

Send us an email: by 4pm Thursday 10 June 2021.

Your feedback may be shared

Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.

We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.